E-LIB Suche - Ergebnisse für: Garimella, Tushar

1

Use of Real‐World Evidence in a Virtual Bridging Analysis f..:

Lu, Zheng ; Wada, Russ ; Salas, Maribel...
The Journal of Clinical Pharmacology. 63 (2023) 11 - p. 1244-1255 , 2023

2

Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Fac..:

Yoshihara, Kazutaka ; Kobayashi, Yoshimasa ; Endo, Seiko...
The Journal of Clinical Pharmacology. 63 (2023) 11 - p. 1232-1243 , 2023

Link: https://doi.org/10.1002/..

3

Exposure‐Response Relationships in Patients With HER2‐Posit..:

Yin, Ophelia ; Iwata, Hiroji ; Lin, Chia‐Chi...
Clinical Pharmacology & Therapeutics. 110 (2021) 4 - p. 986-996 , 2021

Link: https://doi.org/10.1002/..

4

Population Pharmacokinetics of Trastuzumab Deruxtecan in Pa..:

Yin, Ophelia ; Xiong, Yuan ; Endo, Seiko...
Clinical Pharmacology & Therapeutics. 109 (2020) 5 - p. 1314-1325 , 2020

Link: https://doi.org/10.1002/..

5

Population Pharmacokinetic Analysis of Daclatasvir, Asunapr..:

Osawa, Mayu ; Ueno, Takayo ; Shiozaki, Tomomi...
Clinical Pharmacology in Drug Development. 8 (2019) 6 - p. 802-817 , 2019

Link: https://doi.org/10.1002/..

6

Safety Exposure‐Response Analysis for Daclatasvir, Asunapre..:

Osawa, Mayu ; Ueno, Takayo ; Shiozaki, Tomomi..
The Journal of Clinical Pharmacology. 59 (2018) 4 - p. 557-565 , 2018

Link: https://doi.org/10.1002/..

7

Population Pharmacokinetic Analysis for Daclatasvir and Asu..:

Osawa, Mayu ; Ueno, Takayo ; Ishikawa, Hiroki..
The Journal of Clinical Pharmacology. 58 (2018) 11 - p. 1468-1478 , 2018

Link: https://doi.org/10.1002/..

8

Population Pharmacokinetic Analysis of Asunaprevir in Subje..:

Zhu, Li ; Li, Hanbin ; Chan, Phyllis...
Infectious Diseases and Therapy. 7 (2018) 2 - p. 261-275 , 2018

Link: https://doi.org/10.1007/..

9

Daclatasvir: A Review of Preclinical and Clinical Pharmacok..:

Gandhi, Yash ; Eley, Timothy ; Fura, Aberra...
Clinical Pharmacokinetics. 57 (2018) 8 - p. 911-928 , 2018

Link: https://doi.org/10.1007/..

10

Exposure‐Response (Efficacy) Analysis of Daclatasvir and As..:

Ueno, Takayo ; Osawa, Mayu ; Imai, Yasuhiko..
The Journal of Clinical Pharmacology. 58 (2018) 11 - p. 1479-1488 , 2018

Link: https://doi.org/10.1002/..

11

Population Pharmacokinetic Analysis of Daclatasvir in Subje..:

Chan, Phyllis ; Li, Hanbin ; Zhu, Li...
Clinical Pharmacokinetics. 56 (2017) 10 - p. 1173-1183 , 2017

Link: https://doi.org/10.1007/..

12

Asunaprevir: An HCV Protease Inhibitor With Preferential Li..:

Eley, Timothy ; Garimella, Tushar ; Li, Wenying.
Clinical Pharmacology in Drug Development. 6 (2017) 2 - p. 195-200 , 2017

Link: https://doi.org/10.1002/..

13

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asun..:

Garimella, Tushar ; Tao, Xiaolu ; Sims, Karen...
Drugs in R&D. 18 (2017) 1 - p. 55-65 , 2017

Link: https://doi.org/10.1007/..

14

A phase 3, open‐label study of daclatasvir plus asunaprevir..:

Wei, Lai ; Zhang, Mingxiang ; Xu, Min...
Journal of Gastroenterology and Hepatology. 31 (2016) 11 - p. 1860-1867 , 2016

Link: https://doi.org/10.1111/..

15

Su1436 Factors Impacting SVR12 for Patients With Advanced C..:

Poordad, Fred ; Fontana, Robert J. ; Schiff, Eugene R....
Gastroenterology. 150 (2016) 4 - p. S1099 , 2016

Link: https://doi.org/10.1016/..